Stocktoria
Anika Therapeutics, Inc. ANIK
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 1985-05-16
Anika Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M |
| Gross profit | $63.8M | $76.0M | $82.5M | $73.2M | $82.9M |
| R&D expense | $25.8M | $25.5M | $21.8M | $18.3M | $27.3M |
| SG&A expense | $49.1M | $55.6M | $59.9M | $51.2M | $74.1M |
| Operating income | -$11.1M | -$5.1M | $844,000 | $3.7M | $2.6M |
| Income tax | $672,000 | $6.1M | $6.6M | $2.1M | -$1.7M |
| Net income | -$10.9M | -$56.4M | -$82.7M | -$14.9M | $4.1M |
| EPS (diluted) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 |
| Operating cash flow | $11.2M | $5.4M | -$1.8M | $4.4M | $8.4M |
| Free cash flow | $4.4M | -$2.3M | -$7.2M | -$3.1M | $3.3M |
| Cash & equivalents | $57.5M | $55.6M | $68.7M | $86.3M | $94.4M |
| Inventory | $18.8M | $23.8M | $24.4M | $39.8M | $36.0M |
| Total assets | $190.3M | $202.7M | $270.6M | $349.1M | $347.5M |
| Shareholders' equity | $143.5M | $154.0M | $212.3M | $285.6M | $287.1M |
Source: SEC EDGAR filings · CIK 0000898437 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.